HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 293: Line 293:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Line 406: Line 406:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 426: Line 426:
|JH_MS
|JH_MS
|
|
|emailed request on 5/1/24 and reminder on 11/25/24. No response as of 9/7/25
|emailed request on 5/1/24 and reminder on 11/25/24. No response as of 9/7/25.
Open to new author
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
|Gordana Raca MD PhD, University of Southern California, Los Angeles
|Gordana Raca MD PhD, University of Southern California, Los Angeles
Line 438: Line 439:
|12/20/23
|12/20/23
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 458: Line 459:
|JH_MS
|JH_MS
|
|
|Open to new author
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
Line 552: Line 556:
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 568: Line 572:
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 584: Line 588:
|5/1/24
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 632: Line 636:
|5/1/24
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 664: Line 668:
|6/11/24
|6/11/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 700: Line 704:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 732: Line 736:
|12/6/24
|12/6/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 944: Line 948:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 976: Line 980:
|5/9/24
|5/9/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 1,009: Line 1,013:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS